Inhibitors of Raf kinase and MEK signaling

Nithya Ramnath, Alex Adjei

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The RAS/RAF/MEK/ERK signaling pathway plays a central role in the regulation of many cellular processes including proliferation, survival, differentiation, apoptosis, motility and metabolism. This pathway is activated by a diverse group of extracellular signals including integrins, growth factor receptors [i.e. epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR)], or cytokines. While RAS, RAF and MEK activity appear restricted to only one class of substrates, ERK activates more than 70 substrates including nuclear transcription factors. Agents targeting the RAS/RAF/MEK/ERK pathway may therefore inhibit oncogenic signaling in tumor cells. However, most pharmacological agents directed against these targets have not been successful in the clinic. The only small molecule in this class to be approved for cancer therapy is sorafenib, which is not a pure RAF kinase inhibitor. To be successful, one may have to approach this pathway from a multi-pronged approach and also tailor therapy according to which component might be the one playing a pivotal role in a particular system. Relatively selective raf kinase inhibitors are entering clinical trials, and one MEK inhibitor, AZD6244 is in phase II clinical trials.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalUpdate on Cancer Therapeutics
Volume2
Issue number3
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

raf Kinases
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
Platelet-Derived Growth Factor Receptors
Phase II Clinical Trials
Growth Factor Receptors
Epidermal Growth Factor Receptor
Integrins
Neoplasms
Transcription Factors
Phosphotransferases
Clinical Trials
Pharmacology
Apoptosis
Cytokines
Therapeutics

Keywords

  • ERK
  • Inhibitors
  • MEK
  • RAF
  • RAS
  • Signal
  • Target
  • Transduction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibitors of Raf kinase and MEK signaling. / Ramnath, Nithya; Adjei, Alex.

In: Update on Cancer Therapeutics, Vol. 2, No. 3, 01.09.2007, p. 111-118.

Research output: Contribution to journalReview article

Ramnath, Nithya ; Adjei, Alex. / Inhibitors of Raf kinase and MEK signaling. In: Update on Cancer Therapeutics. 2007 ; Vol. 2, No. 3. pp. 111-118.
@article{bdfad98114ab457e88fc82e4ba91b53d,
title = "Inhibitors of Raf kinase and MEK signaling",
abstract = "The RAS/RAF/MEK/ERK signaling pathway plays a central role in the regulation of many cellular processes including proliferation, survival, differentiation, apoptosis, motility and metabolism. This pathway is activated by a diverse group of extracellular signals including integrins, growth factor receptors [i.e. epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR)], or cytokines. While RAS, RAF and MEK activity appear restricted to only one class of substrates, ERK activates more than 70 substrates including nuclear transcription factors. Agents targeting the RAS/RAF/MEK/ERK pathway may therefore inhibit oncogenic signaling in tumor cells. However, most pharmacological agents directed against these targets have not been successful in the clinic. The only small molecule in this class to be approved for cancer therapy is sorafenib, which is not a pure RAF kinase inhibitor. To be successful, one may have to approach this pathway from a multi-pronged approach and also tailor therapy according to which component might be the one playing a pivotal role in a particular system. Relatively selective raf kinase inhibitors are entering clinical trials, and one MEK inhibitor, AZD6244 is in phase II clinical trials.",
keywords = "ERK, Inhibitors, MEK, RAF, RAS, Signal, Target, Transduction",
author = "Nithya Ramnath and Alex Adjei",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.uct.2007.10.001",
language = "English (US)",
volume = "2",
pages = "111--118",
journal = "Update on Cancer Therapeutics",
issn = "1872-115X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Inhibitors of Raf kinase and MEK signaling

AU - Ramnath, Nithya

AU - Adjei, Alex

PY - 2007/9/1

Y1 - 2007/9/1

N2 - The RAS/RAF/MEK/ERK signaling pathway plays a central role in the regulation of many cellular processes including proliferation, survival, differentiation, apoptosis, motility and metabolism. This pathway is activated by a diverse group of extracellular signals including integrins, growth factor receptors [i.e. epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR)], or cytokines. While RAS, RAF and MEK activity appear restricted to only one class of substrates, ERK activates more than 70 substrates including nuclear transcription factors. Agents targeting the RAS/RAF/MEK/ERK pathway may therefore inhibit oncogenic signaling in tumor cells. However, most pharmacological agents directed against these targets have not been successful in the clinic. The only small molecule in this class to be approved for cancer therapy is sorafenib, which is not a pure RAF kinase inhibitor. To be successful, one may have to approach this pathway from a multi-pronged approach and also tailor therapy according to which component might be the one playing a pivotal role in a particular system. Relatively selective raf kinase inhibitors are entering clinical trials, and one MEK inhibitor, AZD6244 is in phase II clinical trials.

AB - The RAS/RAF/MEK/ERK signaling pathway plays a central role in the regulation of many cellular processes including proliferation, survival, differentiation, apoptosis, motility and metabolism. This pathway is activated by a diverse group of extracellular signals including integrins, growth factor receptors [i.e. epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR)], or cytokines. While RAS, RAF and MEK activity appear restricted to only one class of substrates, ERK activates more than 70 substrates including nuclear transcription factors. Agents targeting the RAS/RAF/MEK/ERK pathway may therefore inhibit oncogenic signaling in tumor cells. However, most pharmacological agents directed against these targets have not been successful in the clinic. The only small molecule in this class to be approved for cancer therapy is sorafenib, which is not a pure RAF kinase inhibitor. To be successful, one may have to approach this pathway from a multi-pronged approach and also tailor therapy according to which component might be the one playing a pivotal role in a particular system. Relatively selective raf kinase inhibitors are entering clinical trials, and one MEK inhibitor, AZD6244 is in phase II clinical trials.

KW - ERK

KW - Inhibitors

KW - MEK

KW - RAF

KW - RAS

KW - Signal

KW - Target

KW - Transduction

UR - http://www.scopus.com/inward/record.url?scp=36549044841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549044841&partnerID=8YFLogxK

U2 - 10.1016/j.uct.2007.10.001

DO - 10.1016/j.uct.2007.10.001

M3 - Review article

VL - 2

SP - 111

EP - 118

JO - Update on Cancer Therapeutics

JF - Update on Cancer Therapeutics

SN - 1872-115X

IS - 3

ER -